DrugPipeline.net has announced the addition of “Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” research report to their website DrugPipeline.net
Bangalore, Karnataka -- (SBWIRE) -- 03/10/2017 -- "Endometriosis - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Endometriosis for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Endometriosis from 2013-2023.
Endometriosis is the abnormal growth of endometrial tissue similar to that which lines the interior of the uterus, but in a location outside of the uterus. It is usually developed in Peritoneum, fallopian tubes, Ovaries, Cul-de-sac (the space behind the uterus), Outer surfaces of the uterus, bladder, ureters, intestines, and rectum.
Worldwide in 2012, 527,600 women were diagnosed with Endometriosis. The mortality rate was 1.7 to 2.4 per 100,000 women. In the United States, as with other developed countries Endometriosis was the most common gynecologic malignancy, with over 60,000 new cases and over 10,000 deaths from the disease in each year.
Lupron, developed by Abbvie is the top selling drug of Endometriosis contributing to majority of the market size. Other top players include Visanne/Dienogest (Bayer Healthcare), Zoladex (AstraZeneca), Synarel (Pfizer) and Depo-SubQ Provera (Pfizer). According to Publisher, the worldwide Endometriosis market is estimated to be USD 1.91 Billion by 2023 at a CAGR of 1.33%.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Endometriosis for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Spanning over 85 pages "Endometriosis - Market Insights, Epidemiology and Market Forecast-2023" report covers Report Introduction, Endometriosis Market Overview at a Glance, Epidemiology of Endometriosis in 7MM, Appendix, Report Methodology. The Report covered companies are - Abbvie Inc, Pfizer Inc, Mochida Pharmaceuticals Co., Ltd., Astrazeneca Plc, Pfizer Inc, Debiopharm International S.A., Abbvie Inc, EndoCeutics Inc, Bayer Healthcare Pharmaceuticals
For more information Visit at: http://www.drugpipeline.net/delveinsight/endometriosis-market-insights-epidemiology-and-market-forecast-2023
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.